Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 628157, 10 pages
http://dx.doi.org/10.1155/2015/628157
Review Article

Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut

Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, 35128 Padova, Italy

Received 24 April 2015; Accepted 21 September 2015

Academic Editor: Hannes Neuwirt

Copyright © 2015 Andrea Michielan and Renata D’Incà. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. C. Savage, “Microbial ecology of the gastrointestinal tract,” Annual Review of Microbiology, vol. 31, pp. 107–133, 1977. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Orel and T. K. Trop, “Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 20, no. 33, pp. 11505–11524, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Stephani, K. Radulovic, and J. H. Niess, “Gut microbiota, probiotics and inflammatory bowel disease,” Archivum Immunologiae et Therapiae Experimentalis, vol. 59, no. 3, pp. 161–177, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Tsai and W. J. Coyle, “The microbiome and obesity: is obesity linked to our gut flora?” Current Gastroenterology Reports, vol. 11, no. 4, pp. 307–313, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. T. J. Borody, S. Paramsothy, and G. Agrawal, “Fecal microbiota transplantation: indications, methods, evidence, and future directions,” Current Gastroenterology Reports, vol. 15, no. 8, article 337, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Escobedo, E. López-Ortiz, and I. Torres-Castro, “Gut microbiota as a key player in triggering obesity, systemic inflammation and insulin resistance,” Revista de Investigación Clínica, vol. 66, no. 5, pp. 450–459, 2014. View at Google Scholar
  7. D. Festi, R. Schiumerini, L. H. Eusebi, G. Marasco, M. Taddia, and A. Colecchia, “Gut microbiota and metabolic syndrome,” World Journal of Gastroenterology, vol. 20, no. 43, pp. 16079–16094, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. J. H. Cummings, J. M. Antoine, F. Azpiroz et al., “PASSCLAIM1—gut health and immunity,” European Journal of Nutrition, vol. 43, supplement 2, pp. ii118–ii173, 2004. View at Publisher · View at Google Scholar
  9. S. C. Bischoff, G. Barbara, W. Buurman et al., “Intestinal permeability—a new target for disease prevention and therapy,” BMC Gastroenterology, vol. 14, article 189, 2014. View at Publisher · View at Google Scholar
  10. L. V. Hooper, D. R. Littman, and A. J. Macpherson, “Interactions between the microbiota and the immune system,” Science, vol. 336, no. 6086, pp. 1268–1273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. C. L. Maynard, C. O. Elson, R. D. Hatton, and C. T. Weaver, “Reciprocal interactions of the intestinal microbiota and immune system,” Nature, vol. 489, no. 7415, pp. 231–241, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. J. E. Fishman, G. Levy, V. Alli, X. Zheng, D. J. Mole, and E. A. Deitch, “The intestinal mucus layer is a critical component of the gut barrier that is damaged during acute pancreatitis,” Shock, vol. 42, no. 3, pp. 264–70, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. G. M. Swank and E. A. Deitch, “Role of the gut in multiple organ failure: bacterial translocation and permeability changes,” World Journal of Surgery, vol. 20, no. 4, pp. 411–417, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. M. Derikx, D. A. van Waardenburg, G. Thuijls et al., “New insight in loss of gut barrier during major non-abdominal surgery,” PLoS ONE, vol. 3, no. 12, Article ID e3954, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Z. Al-Bahrani, A. Darwish, N. Hamza et al., “Gut barrier dysfunction in critically ill surgical patients with abdominal compartment syndrome,” Pancreas, vol. 39, no. 7, pp. 1064–1069, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. J. J. de Haan, T. Lubbers, J. P. Derikx et al., “Rapid development of intestinal cell damage following severe trauma: a prospective observational cohort study,” Critical Care, vol. 13, no. 3, article R86, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Camilleri, K. Lasch, and W. Zhou, “Irritable bowel syndrome: methods, mechanisms, and pathophysiology: the confluence of increased permeability, inflammation, and pain in irritable bowel syndrome,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 303, no. 7, pp. G775–G785, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Martínez, B. Lobo, M. Pigrau et al., “Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier,” Gut, vol. 62, no. 8, pp. 1160–1168, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. Z. Mujagic, S. Ludidi, D. Keszthelyi et al., “Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders,” Alimentary Pharmacology and Therapeutics, vol. 40, no. 3, pp. 288–297, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Scarpellini, M. Lupo, C. Iegri, A. Gasbarrini, A. De Santis, and J. Tack, “Intestinal permeability in non-alcoholic fatty LIVER disease: the gut-liver axis,” Reviews on Recent Clinical Trials, vol. 9, no. 3, pp. 141–147, 2014. View at Google Scholar · View at Scopus
  21. K. Ray, “NAFLD: leaky guts: intestinal permeability and NASH,” Nature Reviews Gastroenterology and Hepatology, vol. 12, no. 3, article 123, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Coskun, “Intestinal epithelium in inflammatory bowel disease,” Frontiers in Medicine, vol. 1, article 24, 2014. View at Publisher · View at Google Scholar
  23. J. Mankertz and J.-D. Schulzke, “Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications,” Current Opinion in Gastroenterology, vol. 23, no. 4, pp. 379–383, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Antoni, S. Nuding, J. Wehkamp, and E. F. Stange, “Intestinal barrier in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 20, no. 5, pp. 1165–1179, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Jäger, E. F. Stange, and J. Wehkamp, “Inflammatory bowel disease: an impaired barrier disease,” Langenbeck's Archives of Surgery, vol. 398, no. 1, pp. 1–12, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. K. R. Groschwitz and S. P. Hogan, “Intestinal barrier function: molecular regulation and disease pathogenesis,” Journal of Allergy and Clinical Immunology, vol. 124, no. 1, pp. 3–22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Roda, A. Sartini, E. Zambon et al., “Intestinal epithelial cells in inflammatory bowel diseases,” World Journal of Gastroenterology, vol. 16, no. 34, pp. 4264–4271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. D. Söderholm, K. H. Peterson, G. Olaison et al., “Epithelial permeability to proteins in the noninflamed ileum of Crohn's disease?” Gastroenterology, vol. 117, no. 1, pp. 65–72, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Y. Salim and J. D. Söderholm, “Importance of disrupted intestinal barrier in inflammatory bowel diseases,” Inflammatory Bowel Diseases, vol. 17, no. 1, pp. 362–381, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. S. H. Lee, “Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases,” Intestinal Research, vol. 13, no. 1, pp. 11–18, 2015. View at Publisher · View at Google Scholar
  31. S. Zeissig, N. Bürgel, D. Günzel et al., “Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease,” Gut, vol. 56, no. 1, pp. 61–72, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Vetrano, M. Rescigno, M. R. Cera et al., “Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease,” Gastroenterology, vol. 135, no. 1, pp. 173–184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. K. L. Edelblum and J. R. Turner, “The tight junction in inflammatory disease: communication breakdown,” Current Opinion in Pharmacology, vol. 9, no. 6, pp. 715–720, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. S. M. Krug, J. D. Schulzke, and M. Fromm, “Tight junction, selective permeability, and related diseases,” Seminars in Cell and Developmental Biology, vol. 36, pp. 166–176, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Tanaka, M. Takechi, H. Kiyonari, G. Shioi, A. Tamura, and S. Tsukita, “Intestinal deletion of Claudin-7 enhances paracellular organic solute flux and initiates colonic inflammation in mice,” Gut, vol. 64, no. 10, pp. 1529–1538, 2015. View at Publisher · View at Google Scholar
  36. H. Schmitz, M. Fromm, C. J. Bentzel et al., “Tumor necrosis factor alpha (TNFα) regulates the epithelial barrier in the human intestinal cell line HT-29/B6,” Journal of Cell Science, vol. 112, part 1, pp. 137–146, 1999. View at Google Scholar · View at Scopus
  37. P. Suenaert, V. Bulteel, L. Lemmens et al., “Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease,” American Journal of Gastroenterology, vol. 97, no. 8, pp. 2000–2004, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Marini, G. Bamias, J. Rivera-Nieves et al., “TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8366–8371, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Heller, P. Florian, C. Bojarski et al., “Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution,” Gastroenterology, vol. 129, no. 2, pp. 550–564, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Su, S. C. Nalle, L. Shen et al., “TNFR2 activates mlck-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis,” Gastroenterology, vol. 145, no. 2, pp. 407–415, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. A. J. M. Watson and K. R. Hughes, “TNF-α-induced intestinal epithelial cell shedding: implications for intestinal barrier function,” Annals of the New York Academy of Sciences, vol. 1258, no. 1, pp. 1–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. R. D. Pullan, G. A. O. Thomas, M. Rhodes et al., “Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis,” Gut, vol. 35, no. 3, pp. 353–359, 1994. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Gersemann, J. Wehkamp, and E. F. Stange, “Innate immune dysfunction in inflammatory bowel disease,” Journal of Internal Medicine, vol. 271, no. 5, pp. 421–428, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. S.-J. Chen, X.-W. Liu, J.-P. Liu, X.-Y. Yang, and F.-G. Lu, “Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier,” World Journal of Gastroenterology, vol. 20, no. 28, pp. 9468–9475, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Braun, I. Treede, D. Gotthardt et al., “Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis,” Inflammatory Bowel Diseases, vol. 15, no. 11, pp. 1705–1720, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. J. M. H. Larsson, H. Karlsson, J. G. Crespo et al., “Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation,” Inflammatory Bowel Diseases, vol. 17, no. 11, pp. 2299–2307, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. J. R. Clamp, G. Fraser, and A. E. Read, “Study of the carbohydrate content of mucus glycoproteins from normal and diseased colons,” Clinical Science, vol. 61, no. 2, pp. 229–234, 1981. View at Publisher · View at Google Scholar · View at Scopus
  48. A. H. Raouf, H. H. Tsai, N. Parker, J. Hoffman, R. J. Walker, and J. M. Rhodes, “Sulphation of colonic and rectal mucin in inflammatory bowel disease: reduced sulphation of rectal mucus in ulcerative colitis,” Clinical Science, vol. 83, no. 5, pp. 623–626, 1992. View at Publisher · View at Google Scholar · View at Scopus
  49. C. A. Müller, I. B. Autenrieth, and A. Peschel, “Innate defenses of the intestinal epithelial barrier,” Cellular and Molecular Life Sciences, vol. 62, no. 12, pp. 1297–1307, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. R. N. Cunliffe, F. R. A. J. Rose, J. Keyte, L. Abberley, W. C. Chan, and Y. R. Mahida, “Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease,” Gut, vol. 48, no. 2, pp. 176–185, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Wehkamp, J. Harder, M. Weichenthal et al., “Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis,” Inflammatory Bowel Diseases, vol. 9, no. 4, pp. 215–223, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. M. J. Koslowski, J. Beisner, E. F. Stange, and J. Wehkamp, “Innate antimicrobial host defense in small intestinal Crohn's disease,” International Journal of Medical Microbiology, vol. 300, no. 1, pp. 34–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Gersemann, J. Wehkamp, K. Fellermann, and E. F. Stange, “Crohn's disease-defect in innate defence,” World Journal of Gastroenterology, vol. 14, no. 36, pp. 5499–5503, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. C. W. Teshima, L. A. Dieleman, and J. B. Meddings, “Abnormal intestinal permeability in Crohn's disease pathogenesis,” Annals of the New York Academy of Sciences, vol. 1258, no. 1, pp. 159–165, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Vivinus-Nébot, G. Frin-Mathy, H. Bzioueche et al., “Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation,” Gut, vol. 63, no. 5, pp. 744–752, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Khor, A. Gardet, and R. J. Xavier, “Genetics and pathogenesis of inflammatory bowel disease,” Nature, vol. 474, no. 7351, pp. 307–317, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. D. Hollander, C. M. Vadheim, E. Brettholz, G. M. Petersen, T. Delahunty, and J. I. Rotter, “Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor,” Annals of Internal Medicine, vol. 105, no. 6, pp. 883–885, 1986. View at Publisher · View at Google Scholar · View at Scopus
  58. G. R. May, L. R. Sutherland, and J. B. Meddings, “Is small intestinal permeability really increased in relatives of patients with Crohn's disease?” Gastroenterology, vol. 104, no. 6, pp. 1627–1632, 1993. View at Google Scholar · View at Scopus
  59. P. Munkholm, E. Langholz, D. Hollander et al., “Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives,” Gut, vol. 35, no. 1, pp. 68–72, 1994. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Peeters, B. Geypens, D. Claus et al., “Clustering of increased small intestinal permeability in families with Crohn's disease,” Gastroenterology, vol. 113, no. 3, pp. 802–807, 1997. View at Publisher · View at Google Scholar · View at Scopus
  61. R. K. Russell and J. Satsangi, “IBD: a family affair,” Best Practice and Research: Clinical Gastroenterology, vol. 18, no. 3, pp. 525–539, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. W. Fries, M. C. Renda, M. A. Lo Presti et al., “Intestinal permeability and genetic determinants in patients, first-degree relatives, and controls in a high-incidence area of Crohn's disease in Southern Italy,” The American Journal of Gastroenterology, vol. 100, no. 12, pp. 2730–2736, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. R. D'Incà, V. Annese, V. Di Leo et al., “Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 10, pp. 1455–1461, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Buhner, C. Buning, J. Genschel et al., “Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation?” Gut, vol. 55, no. 3, pp. 342–347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. D. Kevans, W. Turpin, K. Madsen et al., “Determinants of intestinal permeability in healthy first-degree relatives of individuals with Crohn's disease,” Inflammatory Bowel Diseases, vol. 21, no. 4, pp. 879–887, 2015. View at Publisher · View at Google Scholar
  66. E. J. Irvine and J. K. Marshall, “Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk,” Gastroenterology, vol. 119, no. 6, pp. 1740–1744, 2000. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Chichlowski and L. P. Hale, “Bacterial-mucosal interactions in inflammatory bowel disease—an alliance gone bad,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 295, no. 6, pp. G1139–G1149, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. J.-P. Hugot, M. Chamaillard, H. Zouali et al., “Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease,” Nature, vol. 411, no. 6837, pp. 599–603, 2001. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Ogura, D. K. Bonen, N. Inohara et al., “A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease,” Nature, vol. 411, no. 6837, pp. 603–606, 2001. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Hampe, A. Franke, P. Rosenstiel et al., “A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1,” Nature Genetics, vol. 39, no. 2, pp. 207–211, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Parkes, J. C. Barrett, N. J. Prescott et al., “Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility,” Nature Genetics, vol. 39, no. 7, pp. 830–832, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. S. A. McCarroll, A. Huett, P. Kuballa et al., “Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease,” Nature Genetics, vol. 40, no. 9, pp. 1107–1112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. T. Petnicki-Ocwieja, T. Hrncir, Y.-J. Liu et al., “Nod2 is required for the regulation of commensal microbiota in the intestine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 37, pp. 15813–15818, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. P. K. Nighot, C. A. Hu, and T. Y. Ma, “Autophagy enhances intestinal epithelial tight junction barrier function by targeting claudin-2 protein degradation,” The Journal of Biological Chemistry, vol. 290, no. 11, pp. 7234–7246, 2015. View at Publisher · View at Google Scholar
  75. B. Willing, J. Halfvarson, J. Dicksved et al., “Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease,” Inflammatory Bowel Diseases, vol. 15, no. 5, pp. 653–660, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Rehman, C. Sina, O. Gavrilova et al., “Nod2 is essential for temporal development of intestinal microbial communities,” Gut, vol. 60, no. 10, pp. 1354–1362, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. F. Fava and S. Danese, “Intestinal microbiota in inflammatory bowel disease: friend of foe?” World Journal of Gastroenterology, vol. 17, no. 5, pp. 557–566, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. T. D. Martin, S. S. M. Chan, and A. R. Hart, “Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature,” Digestive Diseases and Sciences, vol. 60, no. 5, pp. 1396–1405, 2015. View at Publisher · View at Google Scholar · View at Scopus
  79. B. K. Rodiño-Janeiro, C. Alonso-Cotoner, M. Pigrau, B. Lobo, M. Vicario, and J. Santos, “Role of corticotropin-releasing factor in gastrointestinal permeability,” Journal of Neurogastroenterology and Motility, vol. 21, no. 1, pp. 33–50, 2015. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Wyatt, H. Vogelsang, W. Hübl, T. Waldhöer, and H. Lochs, “Intestinal permeability and the prediction of relapse in Crohn's disease,” The Lancet, vol. 341, no. 8858, pp. 1437–1439, 1993. View at Publisher · View at Google Scholar · View at Scopus
  81. R. D'Incà, V. Di Leo, D. Martines et al., “Can permeability to sugars predict relapses in Crohn's disease?” Gut, vol. 34, no. 1, supplement, pp. S50–S73, 1993. View at Google Scholar
  82. R. D'Incà, V. Di Leo, G. Corrao et al., “Intestinal permeability test as a predictor of clinical course in Crohn's disease,” The American Journal of Gastroenterology, vol. 94, no. 10, pp. 2956–2960, 1999. View at Publisher · View at Google Scholar · View at Scopus
  83. V. Di Leo, R. D'Incà, N. Diaz-Granado et al., “Lactulose/mannitol test has high efficacy for excluding organic causes of chronic diarrhea,” The American Journal of Gastroenterology, vol. 98, no. 10, pp. 2245–2252, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. R. Caccaro, R. D'Incà, M. Martinato et al., “Fecal lactoferrin and intestinal permeability are effective non-invasive markers in the diagnostic work-up of chronic diarrhea,” BioMetals, vol. 27, no. 5, pp. 1069–1076, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. S. O. Ukabam, J. R. Clamp, and B. T. Cooper, “Abnormal small intestinal permeability to sugars in patients with Crohn’s disease of the terminal ileum and colon,” Digestion, vol. 27, no. 2, pp. 70–74, 1983. View at Publisher · View at Google Scholar · View at Scopus
  86. F. Andre, C. Andre, Y. Emery, J. Forichon, L. Descos, and Y. Minaire, “Assessment of the lactulose—mannitol test in Crohn's disease,” Gut, vol. 29, no. 4, pp. 511–515, 1988. View at Publisher · View at Google Scholar · View at Scopus
  87. J. Wyatt, G. Oberhuber, S. Pongratz et al., “Increased gastric and intestinal permeability in patients with Crohn's disease,” American Journal of Gastroenterology, vol. 92, no. 10, pp. 1891–1896, 1997. View at Google Scholar · View at Scopus
  88. J. B. Meddings, L. R. Sutherland, N. I. Byles, and J. L. Wallace, “Sucrose: a novel permeability marker for gastroduodenal disease,” Gastroenterology, vol. 104, no. 6, pp. 1619–1626, 1993. View at Google Scholar · View at Scopus
  89. K. van Wijck, T. J. M. Verlinden, H. M. H. van Eijk et al., “Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: a randomized controlled crossover trial,” Clinical Nutrition, vol. 32, no. 2, pp. 245–251, 2013. View at Publisher · View at Google Scholar · View at Scopus
  90. I. Bjarnason, C. O'Morain, A. J. Levi, and T. J. Peters, “Absorption of 51-chromium-label ethylenediaminoacetate in inflammatory bowel disease,” Gastroenterology, vol. 85, no. 2, pp. 318–322, 1983. View at Google Scholar
  91. R. T. Jenkins, J. K. Ramage, D. B. Jones, S. M. Collins, R. L. Goodacre, and R. H. Hunt, “Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease,” Clinical and Investigative Medicine, vol. 11, no. 2, pp. 151–155, 1988. View at Google Scholar · View at Scopus
  92. L. Pironi, M. Miglioli, E. Ruggeri et al., “Relationship between intestinal permeability to [51Cr]EDTA and inflammatory activity in asymptomatic patients with Crohn's disease,” Digestive Diseases and Sciences, vol. 35, no. 5, pp. 582–588, 1990. View at Publisher · View at Google Scholar · View at Scopus
  93. V. Becker, S. von Delius, M. Bajbouj, A. Karagianni, R. M. Schmid, and A. Meining, “Intravenous application of fluorescein for confocal laser scanning microscopy: evaluation of contrast dynamics and image quality with increasing injection-to-imaging time,” Gastrointestinal Endoscopy, vol. 68, no. 2, pp. 319–323, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. M. I. Canto, S. Anandasabapathy, W. Brugge et al., “In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial (with video),” Gastrointestinal Endoscopy, vol. 79, no. 2, pp. 211–221, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. G. H. Bok, S. R. Jeon, J. Y. Cho et al., “The accuracy of probe-based confocal endomicroscopy versus conventional endoscopic biopsies for the diagnosis of superficial gastric neoplasia (with videos),” Gastrointestinal Endoscopy, vol. 77, no. 6, pp. 899–908, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. M. W. Shahid, A. M. Buchner, M. G. Heckman et al., “Diagnostic accuracy of probe-based confocal laser endomicroscopy and narrow band imaging for small colorectal polyps: a feasibility study,” The American Journal of Gastroenterology, vol. 107, no. 2, pp. 231–239, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. M. W. Shahid, A. M. Buchner, E. Coron et al., “Diagnostic accuracy of probe-based confocal laser endomicroscopy in detecting residual colorectal neoplasia after EMR: a prospective study,” Gastrointestinal Endoscopy, vol. 75, no. 3, pp. 525.e1–533.e1, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. R. W. L. Leong, “Confocal endomicroscopy in the evaluation of celiac disease,” Endoscopy, vol. 42, no. 7, article 607, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. A. Zambelli, V. Villanacci, E. Buscarini, G. Bassotti, and L. Albarello, “Collagenous colitis: a case series with confocal laser microscopy and histology correlation,” Endoscopy, vol. 40, no. 7, pp. 606–608, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Fritscher-Ravens, D. Schuppan, M. Ellrichmann et al., “Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome,” Gastroenterology, vol. 147, no. 5, pp. 1012–1020.e3, 2014. View at Publisher · View at Google Scholar · View at Scopus
  101. R. Kiesslich, M. Goetz, E. M. Angus et al., “Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy,” Gastroenterology, vol. 133, no. 6, pp. 1769–1778, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. J. J. Liu, K. L. Madsen, P. Boulanger, L. A. Dieleman, J. Meddings, and R. N. Fedorak, “Mind the gaps. Confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease,” Journal of Clinical Gastroenterology, vol. 45, no. 3, pp. 240–245, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. L. G. Lim, J. Neumann, T. Hansen et al., “Confocal endomicroscopy identifies loss of local barrier function in the duodenum of patients with Crohn's disease and ulcerative colitis,” Inflammatory Bowel Diseases, vol. 20, no. 5, pp. 892–900, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. R. Kiesslich, C. A. Duckworth, D. Moussata et al., “Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease,” Gut, vol. 61, no. 8, pp. 1146–1153, 2012. View at Publisher · View at Google Scholar · View at Scopus
  105. A. Buda, G. Hatem, H. Neumann et al., “Confocal laser endomicroscopy for prediction of disease relapse in ulcerative colitis: a pilot study,” Journal of Crohn's and Colitis, vol. 8, no. 4, pp. 304–311, 2014. View at Publisher · View at Google Scholar · View at Scopus
  106. P. Suenaert, V. Bulteel, S. Vermeire, M. Noman, G. Van Assche, and P. Rutgeerts, “Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent,” Inflammatory Bowel Diseases, vol. 11, no. 7, pp. 667–673, 2005. View at Publisher · View at Google Scholar · View at Scopus
  107. I. R. Sanderson, P. Boulton, I. Menzies, and J. A. Walker-Smith, “Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet,” Gut, vol. 28, no. 9, pp. 1073–1076, 1987. View at Publisher · View at Google Scholar · View at Scopus
  108. K. Teahon, P. Smethurst, M. Pearson, A. J. Levi, and I. Bjarnason, “The effect of elemental diet on intestinal permeability and inflammation in Crohn's disease,” Gastroenterology, vol. 101, no. 1, pp. 84–89, 1991. View at Google Scholar · View at Scopus
  109. C. A. Chapman-Kiddell, P. S. W. Davies, L. Gillen, and G. L. Radford-Smith, “Role of diet in the development of inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 16, no. 1, pp. 137–151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. M. A. Hildebrandt, C. Hoffmann, S. A. Sherrill-Mix et al., “High-fat diet determines the composition of the murine gut microbiome independently of obesity,” Gastroenterology, vol. 137, no. 5, pp. 1716.e2–1724.e2, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. M. Serino, E. Luche, S. Gres et al., “Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota,” Gut, vol. 61, no. 4, pp. 543–553, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. M. Martinez-Medina, J. Denizot, N. Dreux et al., “Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation,” Gut, vol. 63, no. 1, pp. 116–124, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. A. Lerner and T. Matthias, “Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease,” Autoimmunity Reviews, vol. 14, no. 6, pp. 479–489, 2015. View at Publisher · View at Google Scholar
  114. M. E. Andrade, R. S. Araújo, P. A. V. de Barros et al., “The role of immunomodulators on intestinal barrier homeostasis in experimental models,” Clinical Nutrition, 2015. View at Publisher · View at Google Scholar
  115. L. Pastorelli, C. D. Salvo, J. R. Mercado, M. Vecchi, and T. T. Pizarro, “Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: Lessons learned from animal models and human genetics,” Frontiers in Immunology, vol. 4, article 280, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. I. A. Finnie, A. D. Dwarakanath, B. A. Taylor, and J. M. Rhodes, “Colonic mucin synthesis is increased by sodium butyrate,” Gut, vol. 36, no. 1, pp. 93–99, 1995. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Barcelo, J. Claustre, F. Moro, J.-A. Chayvialle, J.-C. Cuber, and P. Plaisancié, “Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon,” Gut, vol. 46, no. 2, pp. 218–224, 2000. View at Publisher · View at Google Scholar · View at Scopus
  118. J. M. Mariadason, D. H. Barkla, and P. R. Gibson, “Effect of short-chain fatty acids on paracellular permeability in Caco-2 intestinal epithelium model,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 272, part 1, no. 4, pp. G705–G712, 1997. View at Google Scholar · View at Scopus
  119. L. Peng, Z. He, W. Chen, I. R. Holzman, and J. Lin, “Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier,” Pediatric Research, vol. 61, no. 1, pp. 37–41, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. H. M. Hamer, D. Jonkers, K. Venema, S. Vanhoutvin, F. J. Troost, and R.-J. Brummer, “Review article: the role of butyrate on colonic function,” Alimentary Pharmacology & Therapeutics, vol. 27, no. 2, pp. 104–119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. S. Plöger, F. Stumpff, G. B. Penner et al., “Microbial butyrate and its role for barrier function in the gastrointestinal tract,” Annals of the New York Academy of Sciences, vol. 1258, no. 1, pp. 52–59, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. A. Venkatraman, B. S. Ramakrishna, A. B. Pulimood, S. Patra, and S. Murthy, “Increased permeability in dextran sulphate colitis in rats: time course of development and effect of butyrate,” Scandinavian Journal of Gastroenterology, vol. 35, no. 10, pp. 1053–1059, 2000. View at Publisher · View at Google Scholar · View at Scopus
  123. P. Vernia, V. Annese, G. Bresci et al., “Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial,” European Journal of Clinical Investigation, vol. 33, no. 3, pp. 244–248, 2003. View at Publisher · View at Google Scholar · View at Scopus
  124. H. Lorenz-Meyer, P. Bauer, C. Nicolay et al., “Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial,” Scandinavian Journal of Gastroenterology, vol. 31, no. 8, pp. 778–785, 1996. View at Publisher · View at Google Scholar · View at Scopus
  125. W. Stremmel, U. Merle, A. Zahn, F. Autschbach, U. Hinz, and R. Ehehalt, “Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis,” Gut, vol. 54, no. 7, pp. 966–971, 2005. View at Publisher · View at Google Scholar · View at Scopus
  126. W. Stremmel, R. Ehehalt, F. Autschbach, and M. Karner, “Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial,” Annals of Internal Medicine, vol. 147, no. 9, pp. 603–610, 2007. View at Publisher · View at Google Scholar · View at Scopus
  127. S. K. Roy, R. H. Behrens, R. Haider et al., “Impact of zinc supplementation on intestinal permeability in Bangladeshi children with acute diarrhoea and persistent diarrhoea syndrome,” Journal of Pediatric Gastroenterology and Nutrition, vol. 15, no. 3, pp. 289–296, 1992. View at Publisher · View at Google Scholar · View at Scopus
  128. A. N. Alam, S. A. Sarker, M. A. Wahed, M. Khatun, and M. M. Rahaman, “Enteric protein loss and intestinal permeability changes in children during acute shigellosis and after recovery: effect of zinc supplementation,” Gut, vol. 35, no. 12, pp. 1707–1711, 1994. View at Publisher · View at Google Scholar · View at Scopus
  129. V. Di Leo, R. D'Incà, M. Barollo et al., “Effect of zinc supplementation on trace elements and intestinal metallothionein concentrations in experimental colitis in the rat,” Digestive and Liver Disease, vol. 33, no. 2, pp. 135–139, 2001. View at Publisher · View at Google Scholar · View at Scopus
  130. G. C. Sturniolo, V. Di Leo, A. Ferronato, A. D'Odorico, and R. D'Inc, “Zinc supplementation tightens ‘leaky gut’ in Crohn's disease,” Inflammatory Bowel Diseases, vol. 7, no. 2, pp. 94–98, 2001. View at Publisher · View at Google Scholar · View at Scopus
  131. G. C. Sturniolo, W. Fries, E. Mazzon, V. Di Leo, M. Barollo, and R. D'Inca, “Effect of zinc supplementation on intestinal permeability in experimental colitis,” Journal of Laboratory and Clinical Medicine, vol. 139, no. 5, pp. 311–315, 2002. View at Publisher · View at Google Scholar · View at Scopus
  132. W. Wang, L. Chen, R. Zhou et al., “Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease,” Journal of Clinical Microbiology, vol. 52, no. 2, pp. 398–406, 2014. View at Publisher · View at Google Scholar · View at Scopus
  133. D. Jonkers, J. Penders, A. Masclee, and M. Pierik, “Probiotics in the management of inflammatory bowel disease. A systematic review of intervention studies in adult patients,” Drugs, vol. 72, no. 6, pp. 803–823, 2012. View at Publisher · View at Google Scholar · View at Scopus
  134. E. G. Vilela, M. D. L. D. A. Ferrari, H. O. D. G. Torres et al., “Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission,” Scandinavian Journal of Gastroenterology, vol. 43, no. 7, pp. 842–848, 2008. View at Publisher · View at Google Scholar · View at Scopus
  135. Z. Zakostelska, M. Kverka, K. Klimesova et al., “Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment,” PLoS ONE, vol. 6, no. 11, Article ID e27961, 2011. View at Publisher · View at Google Scholar · View at Scopus
  136. R. M. Patel, L. S. Myers, A. R. Kurundkar, A. Maheshwari, A. Nusrat, and P. W. Lin, “Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function,” American Journal of Pathology, vol. 180, no. 2, pp. 626–635, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. S. N. Ukena, A. Singh, U. Dringenberg et al., “Probiotic Escherichia coli nissle 1917 inhibits leaky gut by enhancing mucosal integrity,” PLoS ONE, vol. 2, no. 12, Article ID e1308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  138. M. Persborn, J. Gerritsen, C. Wallon, A. Carlsson, L. M. A. Akkermans, and J. D. Söderholm, “The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis,” Alimentary Pharmacology and Therapeutics, vol. 38, no. 7, pp. 772–783, 2013. View at Publisher · View at Google Scholar · View at Scopus
  139. K. Machiels, M. Joossens, J. Sabino et al., “A decrease of the butyrate-producing species roseburia hominis and faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis,” Gut, vol. 63, no. 8, pp. 1275–1283, 2014. View at Publisher · View at Google Scholar · View at Scopus
  140. P. Marteau, “Butyrate-producing bacteria as pharmabiotics for inflammatory bowel disease,” Gut, vol. 62, no. 12, article 1673, 2013. View at Publisher · View at Google Scholar · View at Scopus
  141. M. Moeinian, S. F. Ghasemi-Niri, S. Mozaffari et al., “Beneficial effect of butyrate, Lactobacillus casei and L-carnitine combination in preference to each in experimental colitis,” World Journal of Gastroenterology, vol. 20, no. 31, pp. 10876–10885, 2014. View at Publisher · View at Google Scholar · View at Scopus
  142. J. D. Simmons, C. Mullighan, K. I. Welsh, and D. P. Jewell, “Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility,” Gut, vol. 47, no. 2, pp. 211–214, 2000. View at Publisher · View at Google Scholar · View at Scopus
  143. R. Dresner-Pollak, Z. Ackerman, R. Eliakim, A. Karban, Y. Chowers, and H. H. Fidder, “The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients,” Genetic Testing, vol. 8, no. 4, pp. 417–420, 2004. View at Publisher · View at Google Scholar · View at Scopus
  144. Y. C. Li, Y. Chen, and J. Du, “Critical roles of intestinal epithelial vitamin D receptor signaling in controlling gut mucosal inflammation,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 148, pp. 179–183, 2015. View at Publisher · View at Google Scholar
  145. S. Wu, Y.-G. Zhang, R. Lu et al., “Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis,” Gut, vol. 64, no. 7, pp. 1082–1094, 2015. View at Publisher · View at Google Scholar · View at Scopus
  146. M. O'Sullivan, “Vitamin D as a novel therapy in inflammatory bowel disease: new hope or false dawn?” Proceedings of the Nutrition Society, vol. 74, no. 1, pp. 5–12, 2015. View at Publisher · View at Google Scholar · View at Scopus